Andrew R. Adams
Mairs & Power Growth Fund
Mairs & Power Growth Fund Eli Lilly and Company stake
total: 96
Mairs & Power Growth Fund LLY trades
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 3
- Reduced:
- 8
- Held since:
- 2019 Q3
- Held for:
- 28 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Mairs & Power Growth Fund holds 138,343 Eli Lilly and Company (LLY) shares with a market value of roughly $165.93M accounting for 2.99% of the overall portfolio. To date, the estimated cost basis is nearly $195.1 for "buy" trades and estimated average "sell" price is $347.56. Mairs & Power Growth Fund first purchased LLY in 2019 Q3, initially acquiring 229,031 shares. Since the initial investment in Eli Lilly and Company (LLY), Mairs & Power Growth Fund has made 11 more transactions.
When did Mairs & Power Growth Fund buy Eli Lilly and Company (LLY)?
Mairs & Power Growth Fund first invested in Eli Lilly and Company (LLY) in 2019 Q3 at the reported quarter-end price of $111.83 per share.
What's the cost basis of Mairs & Power Growth Fund's LLY stake?
The estimated cost basis for Eli Lilly and Company (LLY) stake is around $195.10 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $195.10
- Weighted AVG sell price:
- $347.56
Mairs & Power Growth Fund's historical trades in Eli Lilly and Company
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
2.54%
|
138,343
|
$919.77
|
$127,243,741
|
-9.31% (-14,196)
|
-0.24%
|
|
2025 Q1
|
2.46%
|
152,539
|
$825.91
|
$125,983,485
|
+22.48% (+28,000)
|
+0.45%
|
|
2023 Q4
|
1.45%
|
124,539
|
$582.92
|
$72,596,274
|
-8.12% (-11,000)
|
-0.14%
|
|
2023 Q3
|
1.62%
|
135,539
|
$537.13
|
$72,802,063
|
-16.33% (-26,461)
|
-0.29%
|
|
2023 Q2
|
1.56%
|
162,000
|
$468.98
|
$75,974,760
|
-19.00% (-38,000)
|
-0.39%
|
|
2023 Q1
|
1.51%
|
200,000
|
$343.42
|
$68,684,000
|
+43.88% (+61,000)
|
+0.46%
|
|
2022 Q3
|
1.06%
|
139,000
|
$323.35
|
$44,945,650
|
-8.55% (-13,000)
|
-0.09%
|
|
2022 Q2
|
1.10%
|
152,000
|
$324.23
|
$49,282,960
|
-40.39% (-103,000)
|
-0.61%
|
|
2020 Q2
|
1.00%
|
$164.18
|
-23.66% (-79,031)
|
|||
|
2020 Q1
|
1.27%
|
$138.72
|
-4.30% (-15,000)
|
|||
|
2019 Q4
|
0.99%
|
$131.43
|
+52.39% (+120,000)
|
|||
|
2019 Q3
|
0.58%
|
$111.83
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.